Medicus Pharma (MDCX) Non-Current Assets (2024 - 2026)
Medicus Pharma's (MDCX) quarterly Non-Current Assets came in at $170733.0 in Q4 2025, down 36.43% YoY from $268571.0 in Q4 2024, and down 13.0% on a QoQ basis from $196249.0 in Q3 2025.
Medicus Pharma (MDCX) Non-Current Assets (2024 - 2026) Analysis & Trends
Medicus Pharma (MDCX) has 2 years of Non-Current Assets data on file, last reported at $170733.0 in Q4 2025.
- Quarterly Non-Current Assets fell 36.43% year-over-year to $170733.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.9 million (changed N/A YoY) and the FY2025 annual result came in at $170733.0, down 36.43% from the prior year.
- Non-Current Assets declined to $170733.0 in Q4 2025, from $196249.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $937897.0 in Q2 2025 to a low of $170733.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 141.29 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 101.45 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 125.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 94.68 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 87.87 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 60.68 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 35.42 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 159.77 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 59.27 Bn |
| 10 | Medicus Pharma | 14.88 Mn | -298,205.43 | - | 10.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.13 Mn |
| Dec 31, 2025 | 170,733.00 |
| Sep 30, 2025 | 196,249.00 |
| Jun 30, 2025 | 937,897.00 |
| Mar 31, 2025 | 570,091.00 |
| Dec 31, 2024 | 268,571.00 |